Form 4: Edwards Lifesciences CEO Receives Major Equity Grants

CEO Bernard J. Zovighian was awarded over 330,000 stock-based incentives, including options and performance rights, as part of a long-term compensation strategy.

Summary

• CEO Bernard J. Zovighian received a significant equity compensation package on May 7, 2026.
• The grant includes 43,800 Restricted Stock Units (RSUs) that vest over four years.
• A grant of 245,300 stock options was issued with an exercise price of $82.76, vesting monthly over 36 months.
• Target performance rights of 43,800 units were granted, with a potential payout ranging from 0% to 200% based on three-year performance goals.
• The reporting person disposed of 9,551 shares to satisfy tax withholding obligations at prices between $82.76 and $83.20.
• A total of 9,711 shares were transferred from direct ownership to a family trust for estate planning purposes.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive indicator of executive alignment and long-term commitment, as the CEO's potential wealth is now more closely tied to the company's future performance.

Positives

• Substantial equity grant aligns the CEO's financial interests directly with long-term shareholder value.
• Performance-based rights incentivize the achievement of specific corporate goals over a three-year period.
• The CEO maintains a significant ownership stake with over 104,000 shares held directly and over 21,000 held via trust.
• Stock options have a 10-year term, suggesting a long-term commitment to the company's growth.

Negatives

• The stock options only provide value if the share price exceeds the $82.76 exercise price.
• Performance rights are subject to total loss (0% payout) if minimum performance thresholds are not met.
• Tax-related share disposals slightly reduced the CEO's direct shareholding.

Risks

• Vesting of 43,800 performance units is contingent upon meeting undisclosed performance goals by May 2029.
• Market volatility could render the 245,300 stock options 'out of the money' if the stock price falls below $82.76.

Future Outlook

The heavy weighting of compensation toward stock options and performance-based units indicates a management focus on long-term stock price appreciation and the achievement of strategic three-year targets.

Management Comments

• The restricted stock units are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
• The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards.

Industry Context

StockSavvy.ai notes that this level of equity compensation is consistent with large-cap medical technology firms, where retaining top-tier executive talent is critical for navigating complex regulatory environments and long-term R&D cycles.

Comparison to Industry Standards

• The use of a 3-year performance window for equity vesting is a standard best practice among S&P 500 companies to satisfy institutional investor requirements.
• The mix of options, RSUs, and performance units is comparable to executive packages at peers such as Medtronic and Abbott Laboratories.
• The 200% cap on performance payouts is a common industry ceiling for high-performing executives.

Related Party Transactions

• Transfer of 9,711 shares from direct ownership to a family trust for no consideration (gift).

Stakeholder Impact

• Shareholders: Interests are aligned with the CEO through performance-based equity.
• Management: CEO is incentivized to remain with the company through a multi-year vesting schedule.

Next Steps

• Monitor the company's quarterly performance to assess the likelihood of the performance rights vesting at or above the 100% target.
• Track the stock price relative to the $82.76 option exercise price to determine the CEO's unrealized gains.

Key Dates

Recommendation

This is a routine administrative filing regarding executive compensation. While it shows management alignment, it does not provide new material information regarding the company's operational health or financial outlook that would trigger a change in investment rating.

Keywords

Edwards Lifesciences, EW, CEO Compensation, Stock Options, Restricted Stock Units, Insider Trading, Bernard Zovighian, Medical Devices